SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP) -- Ignore unavailable to you. Want to Upgrade?


To: Larry Liebman who wrote (244)1/20/1999 1:57:00 AM
From: Miljenko Zuanic  Read Replies (1) | Respond to of 626
 
400 mm in first year?



To: Larry Liebman who wrote (244)1/20/1999 2:47:00 AM
From: scaram(o)uche  Respond to of 626
 
The competitive scenario has changed since we first started discussing ilo. It could, if the side-effect profile looks clean enough, break through into rapid penetration of a larger market than we originally thought about, back when we were posting in the other Titan thread. MZ's been watching it evolve.



To: Larry Liebman who wrote (244)1/20/1999 9:58:00 PM
From: LLCF  Read Replies (1) | Respond to of 626
 
<CFO confirmed that royalties for Iloperidone/Novartis will be 10% (of what they anticipate will be "minimally" a $400 million market). >

So $40 mill yr to TTP? Why is this stock so freakin cheap?

DAK